admin

India is not worried about some European Union countries suspending the use of the AstraZeneca COVID-19 vaccine and will continue to roll out the shot in its huge immunisation programme “with full vigour”, a senior official said.

The AstraZeneca shots are produced by India’s Serum Institute and known in the country as Covishield. The vaccine accounts for most of the 35 million coronavirus jabs administered in the country so far.

But the European nations, including France, Spain and Germany, have suspended the vaccine’s use because of worries it causes blood clots.

This is despite the World Health Organization saying that the vaccine is safe and the EU’s medicines regulator is “firmly convinced” that the benefits outweigh the risks of side-effects.

Vinod K Paul, a member of the Indian government’s advisory body, NITI Aayog, said on Wednesday that Indian authorities were reviewing data but that there was nothing to suggest a “causal relationship” between the vaccine and blood clots.

“(I) again assure you that we have no signal of concern in this regard and therefore clearly, our programme (with the vaccine)… will go on with full vigour,” Paul told reporters.

India was “watching the information being made available from other sources, but today there is no concern at all”, he said.

The Serum Institute – the world’s largest vaccine producer – has already supplied tens of millions of doses of the AstraZeneca vaccine to dozens of mostly poorer countries around the world.

Meanwhile, Indian Prime Minister Narendra Modi on Wednesday ordered ramping up surveillance and testing to stop an emerging second peak of coronavirus infections.

During a virtual conference with leaders of Indian states, Modi warned that the country was at risk of a nationwide outbreak if authorities did not curb the localised surges.

“If we don’t stop this increasing pandemic right now, then we can face a nationwide outbreak situation. We will have to immediately stop the second peak of coronavirus cases that is now forming. And to do so, we need to take quick and decisive steps,” he said.

India reported 35,871 new coronavirus cases on Thursday, the highest in more than three months, with the worst-affected state of Maharashtra alone accounting for 65 percent of that.

Total infections have now risen to 11.47 million, the highest after the United States and Brazil. Deaths rose by 172 to 159,216, data from the health ministry showed.

Moderna Inc said it has begun delivering experimental doses of its COVID-19 vaccine to children as part of a study to determine whether it is safe and effective in those as young as six months.

The trial aims to enrol about 6,750 volunteers in the US and Canada. The US’s National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority are collaborating with the company, Moderna said in a statement.

Aljazeera reports that in the first stage of the trial, researchers will test various doses of vaccine to see which works best. Study participants between the ages of 2 and 11 will receive either 50 or 100 microgrammes per dose, while those ages six months to just under 24 months will get 25, 50 or 100 microgrammes per dose.

All doses will be administered twice, 28 days apart.

For the sake of comparison, each Moderna dose for adults contains 0.5 millilitres of the vaccine, equivalent to 500 microgrammes.

Researchers will analyse the data from the first phase of the trial to determine which doses to give to children and toddlers in the second phase of the study. In that part of the study, participants will be randomly assigned to receive either the vaccine or a saline placebo. Then they will be tracked for a year to see whether the vaccine works better than the placebo.

If it turns out that the risk of developing COVID-19 is significantly lower among children who get the vaccine than among children who get the placebo, the researchers will be able to compare those two groups and calculate how much the risk is reduced by the vaccine. The more the risk is reduced, the more effective the vaccine.

However, COVID-19 is less likely to strike children than adults.

“This paediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine in this younger age population,” Moderna CEO Stephane Bancel said.

Although children make up about 22 percent of the US population, they account for just 11.6 percent of COVID-19 cases, according to data from the Centers for Disease Control and Prevention. And cases for all age groups, including children, are expected to fall as vaccines roll out to adults and the country gets closer to achieving herd immunity.

Those factors may mean that there will not be enough cases of COVID-19 among clinical trial participants for researchers to make a statistically significant calculation of vaccine efficacy. In that case, the study team will also examine the immune response of children in the trial and compare it to that of adults. If the children generate enough antibodies compared with adults, the researchers will take that as evidence of vaccine effectiveness.

Parents interested in having their children join the trial can find more information about it at www.kidcovestudy.com. The trial is expected to continue through June of 2023.

Pfizer and BioNTech are currently testing their COVID-19 vaccine in children as young as 12. Their initial clinical trial included 16 and 17-year-olds, and the vaccine is currently the only one authorised for use for minors in the US.

Johnson & Johnson plans to test both single and two-dose regimens of its vaccine in children ages 12 to 17, according to the Food and Drug Administration.